Sirolimus News and Research

RSS
European Congress of Nephrology unveils results of various clinical trials

European Congress of Nephrology unveils results of various clinical trials

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

Immunosuppressive drug sirolimus improves kidney health of patients with ADPKD: Study

Immunosuppressive drug sirolimus improves kidney health of patients with ADPKD: Study

Drug-releasing stents do not result in fewer deaths or subsequent heart attacks after angioplasty

Drug-releasing stents do not result in fewer deaths or subsequent heart attacks after angioplasty

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Watson Laboratories sued in connection with filing of ANDA for generic version of Rapamune tablets

Watson Laboratories sued in connection with filing of ANDA for generic version of Rapamune tablets

SurModics reports second-quarter GAAP revenue of $18.4 million, up 6% sequentially

SurModics reports second-quarter GAAP revenue of $18.4 million, up 6% sequentially

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Sirolimus-based immunosuppression improves survivals after transplantation for HCC

Sirolimus-based immunosuppression improves survivals after transplantation for HCC

New therapies increase survival rates in post-transplant liver cancer patients

New therapies increase survival rates in post-transplant liver cancer patients

CYPHER Sirolimus-eluting Coronary Stent demonstrates efficacy advantages over Medtronic's Endeavor

CYPHER Sirolimus-eluting Coronary Stent demonstrates efficacy advantages over Medtronic's Endeavor

Drug-eluting stents offer new hope to patients with critical limb ischemia

Drug-eluting stents offer new hope to patients with critical limb ischemia

CYPHER Sirolimus-eluting Coronary Stent provides better outcome compared to Medtronic’s Endeavor Stent

CYPHER Sirolimus-eluting Coronary Stent provides better outcome compared to Medtronic’s Endeavor Stent

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

UCSB research: Rapamycin drug, a potential treatment for ADPKD

UCSB research: Rapamycin drug, a potential treatment for ADPKD

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

Bortezomib can improve control of GVHD and immune system recovery

Bortezomib can improve control of GVHD and immune system recovery

Switching to new immunosuppressant drug may reduce skin cancer after kidney transplantation

Switching to new immunosuppressant drug may reduce skin cancer after kidney transplantation